<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">  <head>    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>    <title>All Interactions with Delavirdine</title><link rel="stylesheet" href="css/insite.css" type="text/css"/><link rel="stylesheet" href="css/layout.css" type="text/css"/><link rel="stylesheet" href="css/topNav.css" type="text/css"/><!-- jquery javascript --><script type="text/javascript" src="script/jquery/load.js"><!--  --></script><script type="text/javascript" src="app-js/jquery.scrollTo.js"> </script><script type="text/javascript" src="app-js/jquery.cycle.js"> </script><script type="text/javascript" language="JavaScript">
        function openWindow(url,name){
            newWin = window.open(url,name,'status,toolbar,menubar,resizable,scrollbars,left=20,top=20,width=650,height=600')
            newWin.focus()
        }

        function openXWindow(url,name){
            newXWin = window.open(url,name)
            newXWin.focus()
        }

		/* BASED ON NEC DEMO.XML */
		   // REVEAL HIDDEN LOGIC QUESTION
				function branchNext (event) {
					$.log("BRANCHNEXT() :  enter");
					var n = $(this).children("input:checked").size();

					if (n)   {
						 var reveal = "." + $($(this).children("input:checked")).attr("name") + "-" + $($(this).children("input:checked")).val();

						 $(reveal).removeClass("hidden").addClass("question-revealed");
					}
			   }

		// HIDE TO-BE-REVEALED LOGIC QUESTIONS
			$(document).ready(function() { hideLogicQuestions($(document).children()[0]) });

			function hideLogicQuestions (element) {
				$.log("hideLogicQuestions() : enter");
				$(".hidden-question").each(function() {
					$(this).addClass("hidden").removeClass("question-revealed");
				});
		   }
		/* END FROM NEC DEMO.XML */


			function expand(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				/* CLOSE ALL SECTIONS AND RESET BUTTONS
				$(".expandable", section).addClass("hidden");
				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
				$(".expandAll", section).removeClass("hidden");
				$(".collapseAll", section).addClass("hidden");
				*/

				// OPEN SPECIFIED SECTION AND UPDATE ITS BUTTONS
				section.removeClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");

				// $(this).siblings(".expandAll").addClass("hidden");
				// $(this).siblings(".collapseAll").removeClass("hidden");
			}
			function collapse(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");

				$(this).siblings(".collapseAll").addClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");
			}

			function expandAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.removeClass("hidden");
				$(".expandable", section).removeClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".expand").addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");
				$(this).siblings(".collapseAll").removeClass("hidden");

				$(".expand", section).addClass("hidden");
				$(".collapse", section).removeClass("hidden");
			}
			function collapseAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(".expandable", section).addClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".collapse").addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");

				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
			}


			// connect the correct fuctions
			function sconnect(element) {
				$(".reveal-question", element).click(branchNext);

				$(".expand", element).click(expand);
				$(".expandAll", element).click(expandAll);
				$(".collapse", element).click(collapse);
				$(".collapseAll", element).click(collapseAll);
			}

			// load method for adding connections
			$(document).ready(function() {
				sconnect($(document).children()[0])
			 });

			 $(document).ready(function(){
			 $('.carousel ul').cycle({'prev':'.previous','next':'.next','play':'.play','pause':'.pause'});
			 $(".carousel-hidden").each(function () {
			 $(this).removeClass("carousel-hidden");
			 });
			 });


		</script><!--*********************************************************
    *************************************************************
    REPLACE GOOGLE ANALYTICS SCRIPT BEFORE PUBLISHING TO LIVESITE
    You can find the script in google-analytics.js **************
    *************************************************************
    **********************************************************--><script type="text/javascript">
   
     var _gaq = _gaq || [];
     _gaq.push(['_setAccount', 'UA-19627862-1']);
     _gaq.push(['_trackPageview']);
   
     (function() {
       var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
       ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
       var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
     })();
   
</script></head><body><div class="floatpage"><div id="ucsf"><a href="http://ucsf.edu/"><img src="images/masthead/ucsf.gif" alt="University of California, San Francisco Logo"/></a><p>University of California, San Francisco | <a href="http://www.ucsf.edu/about-ucsf/">About UCSF</a> | <a href="http://www.ucsf.edu/ucsf/search">Search UCSF</a> | <a href="http://www.ucsfhealth.org/">UCSF Medical Center</a></p></div><div id="header"><div style="float:left;"><a href="InSite" style="display:block;"><img src="images/masthead/splash-logo-top.gif" alt="HIV InSite"/></a><h1 class="site-description" style="clear:both; width: 475px;">Comprehensive, up-to-date information on HIV/AIDS treatment and prevention from the University of California San Francisco</h1></div><div class="site-sub-navigation"><a href="InSite">Home</a> | <a href="InSite?page=pb-00-00">Patient/Public</a> | <a href="InSite?page=Audio">Audio</a> | <a href="InSite?page=News">News</a> | <a href="InSite?page=Links">Links</a></div><div class="sitesearch"><form action="search" method="get" id="search"><input type="hidden" name="page" value="sr-00-00"/><input type="hidden" name="post" value="1"/><label for="SearchEntry">Search</label><input type="text" size="28" name="SearchEntry" id="SearchEntry" aria-label="Search"/><input type="submit" id="I1" value="Search" style="margin-left: 5px;"/></form></div><div id="site-navigation"><ul><li class="site-navigation"><a href="InSite?page=KB">Knowledge Base</a></li><li class="site-navigation"><a href="InSite?page=Treatment">Treatment</a></li><li class="site-navigation"><a href="InSite?page=Prevention">Prevention</a></li><li class="site-navigation"><a href="InSite?page=Policy">Policy Analysis</a></li><li class="site-navigation"><a href="InSite?page=cr-00-00">Global Response</a></li></ul></div></div><div id="content-target"><div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="right"><font face="Arial, Helvetica" size="-2"><a href="http://hivinsite.ucsf.edu/InSite">Home</a> &gt; <a href="http://hivinsite.ucsf.edu/InSite?page=Treatment">Treatment</a> &gt; <a href="InSite?page=ar-00-02">Interactions</a></font></td></tr><tr><td><img alt="" src="images/transparent.gif" border="0" height="10" width="1"/></td></tr></tbody></table><div class="pgtitle">Database of Antiretroviral Drug Interactions</div><img alt="" src="images/greyline.gif"/><br/><p style="margin-top:0;padding-top:0;" class="kbrsec1">All Interactions with Delavirdine (Rescriptor)</p><table class="datatable" width="100%"><thead><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr></thead><tr><td valign="top" width="10%">Alprazolam<sup><a href="#88">88</a></sup><div>(Xanax)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase alprazolam levels</td><td valign="top">-</td><td valign="top">Increased alprazolam effects (eg, increased sedation, confusion, respiratory depression)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Avoid combination; consider alternative agents</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Lorazepam</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Amprenavir<sup><a href="#60">60</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase amprenavir levels</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Amprenavir<sup><a href="#141">141</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">450 mg BID x 10 days</td><td valign="top">1000 mg BID x 10 days</td><td valign="top">Amprenavir AUC: increased 20%</td><td valign="top">Delavirdine AUC: increased 126%; Cmin: increased 372%; Cmax: increased 115%(compared to amprenavir 600 mg and delavirdine 600 mg BID)</td><td valign="top">Increased delavirdine effects</td><td valign="top">Inhibition of CYP450 3A4 by amprenavir</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Amprenavir<sup><a href="#109">109</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">600 mg BID</td><td valign="top">600 mg BID</td><td valign="top">Amprenavir AUC: increased 130%; Cmax: increased 40%; Cmin: increased 125%</td><td valign="top">Delavirdine AUC: decreased 61%; Cmax: decreased 47%; Cmin: decreased 88%</td><td valign="top">Decreased delavirdine and increased amprenavir effects</td><td valign="top">Induction of CYP450 3A4 by amprenavir and inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Amprenavir<sup><a href="#110">110</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">600 mg BID</td><td valign="top">600 mg BID</td><td valign="top">Amprenavir AUC: increased 30%; Cmax: increased 18%; Cmin: increased 90%</td><td valign="top">Delavirdine AUC: decreased 50%; Cmax: decreased 30%; Cmin: decreased 70%</td><td valign="top">Decreased delavirdine and increased amprenavir effects</td><td valign="top">Induction of CYP450 3A4 by amprenavir and inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Antacids<sup><a href="#88">88</a></sup><div>(Maalox, Mylanta, Riopan, Milk of Magnesia, others)</div></td><td valign="top">-</td><td valign="top">300 mg x 1 dose</td><td valign="top">Not studied</td><td valign="top">Delavirdine AUC: decreased 41%</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Decreased absorption of delavirdine</td><td valign="top"><p>Separate antacid dose by at least 1 hour before or 2 hours after delavirdine</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Astemizole<sup><a href="#88">88</a></sup><div>(Hismanal)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied; may increase astemizole levels</td><td valign="top">- </td><td valign="top">Increased astemizole effects (eg, cardiac arrhythmias)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Cetirizine Fexofenadine Loratadine</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Carbamazepine<sup><a href="#88">88</a></sup><div>(others)(Tegretol)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Delavirdine Cmin: decreased</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Induction of CYP450 3A4 by carbamazepine</td><td valign="top"><p>Avoid combination if possible; consider alternative agents; monitor carbamazepine levels and adjust as indicated</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Gabapentin Lamotrigine Tiagabine Topiramate</b></p></td></tr><tr><td valign="top" width="10%">Cimetidine<sup><a href="#88">88</a></sup><div>(Tagamet)(Tagamet)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may decrease delavirdine absorption</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Decreased absorption of delavirdine</td><td valign="top"><p>Consider alternative agents</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Famotidine Nizatidine Ranitidine</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Cisapride<sup><a href="#88">88</a></sup><div>(Propulsid)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase cisapride levels</td><td valign="top">-</td><td valign="top">Increased cisapride effects (eg, cardiac arrhythmias)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Metoclopramide</b></p></td></tr><tr><td valign="top" width="10%">Clarithromycin<sup><a href="#88">88</a></sup><div>(Biaxin)</div></td><td valign="top">500 mg BID</td><td valign="top">300 mg TID</td><td valign="top">Clarithromycin AUC: increased 100%;14-hydroxy clarithromycin AUC: decreased 75%</td><td valign="top">Delavirdine AUC: increased 44%</td><td valign="top">Not studied</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>-</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Co-trimoxazole<sup><a href="#88">88</a></sup><div>(TMP/SMX, Trimethoprim/Sulfamethoxazole)(Bactrim, Septra)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Dapsone<sup><a href="#88">88</a></sup><div>(others)(Avlosulfon)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase dapsone levels</td><td valign="top">-</td><td valign="top">Increased dapsone effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Didanosine<sup><a href="#19">19</a></sup><div>(ddI)(Videx)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied</td><td valign="top">Delavirdine AUC: decreased 20%</td><td valign="top">Decreased delavirdine effects</td><td valign="top">-</td><td valign="top"><p>Consider didanosine EC or administer delavirdine at least 1 hour prior to didanosine tablets/suspension</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Didanosine<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(ddI)(Videx)</div></td><td valign="top">125 or 200 mg (buffered formulation) Q12H</td><td valign="top">400 mg x 1 dose</td><td valign="top">Not studied</td><td valign="top">Delavirdine AUC: decreased 32%; Cmax: decreased 53%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Didanosine<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(ddI)(Videx)</div></td><td valign="top">125 or 200 mg (buffered formulation) Q12H</td><td valign="top">400 mg x 1 dose (administered 1 hr before didanosine)</td><td valign="top">Not studied</td><td valign="top">Delavirdine AUC: increased 20%; Cmax: increased 18%</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Didanosine<sup><a href="#84">84</a>, <a href="#19">19</a>, <a href="#88">88</a></sup><div>(ddI)(Videx)</div></td><td valign="top">125 or 250 mg BID x 28 days</td><td valign="top">400 mg TID x 28 days</td><td valign="top">Didanosine AUC: decreased 21%; Cmax: decreased 20%</td><td valign="top">Delavirdine AUC: decreased 19%; Cmax: decreased 32%</td><td valign="top">- </td><td valign="top">Decreased didanosine and delavirdine absorption</td><td valign="top"><p>Separate didanosine and delavirdine doses by at least 1 hour</p><p class="warn"><b> </b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ergotamine<sup><a href="#88">88</a></sup><div>(Cafergot, Ergot derivatives)(Cafergot, others)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase ergotamine levels</td><td valign="top">-</td><td valign="top">Increased ergotamine effects (eg, ergotism)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>5-HT agonists ("triptans")</b></p></td></tr><tr><td valign="top" width="10%">Famotidine<sup><a href="#88">88</a></sup><div>(Pepcid)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied; may decrease delavirdine absorption</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Decreased absorption of delavirdine</td><td valign="top"><p>Avoid chronic coadministration</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Local antacids</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Fluconazole<sup><a href="#88">88</a></sup><div>(Diflucan)(Diflucan)</div></td><td valign="top">400 mg x 1 dose</td><td valign="top">300 mg TID</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Fluoxetine<sup><a href="#88">88</a></sup><div>(Prozac)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Delavirdine Cmin: increased 50%</td><td valign="top">Increased delavirdine effects</td><td valign="top">Inhibition of CYP450 3A4 by fluoxetine</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Indinavir<sup><a href="#16">16</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">400 mg TID x 7 days</td><td valign="top">400 mg TID</td><td valign="top">Indinavir AUC: no signficant change; Cmax: decreased 36%; Cmin: increased 118%</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Decrease indinavir to 600 mg Q8H</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Indinavir<sup><a href="#88">88</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">400 mg x 1 dose</td><td valign="top">400 mg TID</td><td valign="top">Indinavir AUC: increased 40%</td><td valign="top">Not studied</td><td valign="top">Increased indinavir effects</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Decrease indinavir to 600 mg Q8H</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Indinavir<sup><a href="#16">16</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">600 mg TID x 7 days</td><td valign="top">400 mg TID</td><td valign="top">Indinavir AUC: increased 53%; Cmax: no significant change; Cmin: increased 298%</td><td valign="top">No significant change</td><td valign="top">Increased indinavir effects</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Decrease indinavir to 600 mg Q8H</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Indinavir<sup><a href="#16">16</a>, <a href="#17">17</a>, <a href="#18">18</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">600 mg x 1 dose</td><td valign="top">400 mg TID</td><td valign="top">Indinavir AUC: increased 44% (compared to 800 mg dose)</td><td valign="top">No significant change</td><td valign="top">Increased indinavir effects</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Decrease indinavir to 600 mg Q8H</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ketoconazole<sup><a href="#88">88</a></sup><div>(Nizoral)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Delavirdine Cmin: increased 50%</td><td valign="top">Increased delavirdine effects</td><td valign="top">Inhibition of CYP450 3A4 by ketoconazole</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#78">78</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase lopinavir/ritonavir levels</td><td valign="top">-</td><td valign="top">Increased lopinavir/ritonavir effects</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Methadone<sup><a href="#204">204</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">40-120 mg QD</td><td valign="top">600 mg BID x 5 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Midazolam<sup><a href="#88">88</a></sup><div>(Versed)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase midazolam levels</td><td valign="top">-</td><td valign="top">Increased midazolam effects (increased sedation, confusion, respiratory depression)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation; chronic midazolam administration (oral or intravenous) should be avoided</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Lorazepam</b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Nelfinavir<sup><a href="#89">89</a></sup><div>(NFV)(Viracept)</div></td><td valign="top">750 mg TID</td><td valign="top">400 mg TID</td><td valign="top">Nelfinavir AUC: increased 72%</td><td valign="top">Delavirdine AUC: decreased 42%; Cmin: decreased 52%</td><td valign="top">Increased nelfinavir effects</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Nifedipine<sup><a href="#88">88</a></sup><div>(Procardia, Adalat)(Adalat, Procardia)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied; may increase nifedipine levels</td><td valign="top">- </td><td valign="top">Increased nifedipine effects (eg, hypotension, heart block)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Monitor and adjust nifedipine as indicated</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Nizatidine<sup><a href="#88">88</a></sup><div>(Axid)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied; may decrease delavirdine levels</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Decreased absorption of delavirdine</td><td valign="top"><p>Avoid chronic coadministration</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Local antacids</b></p></td></tr><tr><td valign="top" width="10%">Phenobarbital<sup><a href="#88">88</a></sup><div>(others)(Luminal)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Delavirdine Cmin: decreased</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Induction of CYP450 3A4 by phenobarbital</td><td valign="top"><p>Avoid combination if possible; consider alternative agents.  If using, monitor and adjust phenobarbital levels as indicated.  </p><p class="warn"><i>Alternative Agents</i>: <br/><b>Gabapentin Lamotrigine Tiagabine Topiramate</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Phenytoin<sup><a href="#88">88</a></sup><div>(Dilantin)(Dilantin)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Delavirdine Cmin: decreased</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Induction of CYP450 3A4 by phenytoin</td><td valign="top"><p>Avoid combination if possible; consider alternative agents; monitor phenytoin levels and adjust as indicated</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Gabapentin Lamotrigine Tiagabine Topiramate</b></p></td></tr><tr><td valign="top" width="10%">Quinidine<sup><a href="#88">88</a></sup><div>(Quindex, others)(Quindex)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied; may increase quinidine levels</td><td valign="top">- </td><td valign="top">Increased quinidine effects (eg, cardiac arrhythmias)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b> </b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ranitidine<sup><a href="#88">88</a></sup><div>(Zantac)(Zantac)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied; may decrease delavirdine levels</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Decreased absorption of delavirdine</td><td valign="top"><p>Avoid chronic coadministration</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Local antacids</b></p></td></tr><tr><td valign="top" width="10%">Rifabutin<sup><a href="#88">88</a></sup><div>(Mycobutin)(Mycobutin)</div></td><td valign="top">300 mg QD</td><td valign="top">400  mg TID</td><td valign="top">Rifabutin AUC: increased 100%</td><td valign="top">Delavirdine AUC: decreased 80%</td><td valign="top">Decreased delavirdine effects; increased rifabutin effects (eg, uveitis)</td><td valign="top">Induction of CYP450 3A4 by rifabutin; inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifampin<sup><a href="#88">88</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">400 mg TID</td><td valign="top">Not studied</td><td valign="top">Delavirdine AUC: decreased 96%</td><td valign="top">Decreased delavirdine effects</td><td valign="top">Induction of CYP450 3A4 by rifampin</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Rifabutin</b></p></td></tr><tr><td valign="top" width="10%">Ritonavir<sup><a href="#59">59</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">100 mg BID x 10 days</td><td valign="top">600 mg BID x 10 days</td><td valign="top">Ritonavir AUC: increased 81%; Cmax: increased 50%; Cmin: increased 113%</td><td valign="top">No significant change</td><td valign="top">Increased ritonavir effects</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ritonavir<sup><a href="#88">88</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">300 mg BID</td><td valign="top">400 or 600 mg BID</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Saquinavir<sup><a href="#88">88</a></sup><div>(SQV)(Fortovase, Invirase)</div></td><td valign="top">600 mg TID</td><td valign="top">400 mg TID</td><td valign="top">Saquinavir AUC: increased 500%</td><td valign="top">Delavirdine AUC: decreased 15%</td><td valign="top">-</td><td valign="top">Increased saquinavir effects</td><td valign="top"><p>-</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Delavirdine</th><th>Effect on Drug Levels</th><th>Effect on Delavirdine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Saquinavir<sup><a href="#44">44</a></sup><div>(SQV)(Fortovase, Invirase)</div></td><td valign="top">600 mg TID (hard gel caps) x 21 days</td><td valign="top">400 mg TID x 14 days</td><td valign="top">Saquinavir AUC: increased 500%</td><td valign="top">No significant change</td><td valign="top">Increased saquinavir effects</td><td valign="top">Inhibition of CYP450 3A4 by delavirdine</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Terfenadine<sup><a href="#88">88</a></sup><div>(Seldane)(Seldane)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied; may increase terfenadine levels</td><td valign="top">- </td><td valign="top">Increased terfenadine effects (eg, cardiac arrhythmias)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Cetirizine Fexofenadine Loratadine</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Triazolam<sup><a href="#88">88</a></sup><div>(Halcion)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied; may increase triazolam levels</td><td valign="top">-</td><td valign="top">Increased triazolam effects (eg, increased sedation, confusion, respiratory depression)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Do not coadminister; consider alternative agents</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Lorazepam Oxazepam Temazepam Trazodone</b></p></td></tr><tr><td valign="top" width="10%">Warfarin<sup><a href="#88">88</a></sup><div>(Coumadin)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">Not studied</td><td valign="top">- </td><td valign="top">Increased warfarin effects (eg, increased INR, increased risk of bleeding)</td><td valign="top">Inhibition of CYP450 3A4 and 2C9 by delavirdine</td><td valign="top"><p>Monitor INR and adjust warfarin as indicated</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Zidovudine<sup><a href="#88">88</a></sup><div>(AZT, ZDV)(Retrovir)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#bbbbbb"><td class="cellleft" colspan="8">"-" indicates that there are no data available
                
            </td></tr></table><table cellspacing="2" cellpadding="0" border="0"><tr><td valign="top" class="cellrightblue"><a name="16"> </a>16:</td><td class="cellleft">Crixivan [package insert]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="17"> </a>17:</td><td class="cellleft">Rescriptor [package insert]. Kalamazoo, MI: Pharmacia &amp; Upjohn Co.; 2001.</td></tr><tr><td valign="top" class="cellrightblue"><a name="18"> </a>18:</td><td class="cellleft">Ferry JJ, Herman BD, Carel BJ, et al. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr. 1998;18:252-259.</td></tr><tr><td valign="top" class="cellrightblue"><a name="19"> </a>19:</td><td class="cellleft">Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003.</td></tr><tr><td valign="top" class="cellrightblue"><a name="44"> </a>44:</td><td class="cellleft">Fortovase [package insert]. Basel, Switzerland: F. Hoffman-La Roche Ltd.;2003.</td></tr><tr><td valign="top" class="cellrightblue"><a name="59"> </a>59:</td><td class="cellleft">Tran JQ, Petersen C, Garrett M, et al. Delavirdine (DLV) significantly increases exposure of low dose ritonavir (RTV) in healthy volunteers [abstract #A-494]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="60"> </a>60:</td><td class="cellleft">Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="78"> </a>78:</td><td class="cellleft">Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="84"> </a>84:</td><td class="cellleft">Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="88"> </a>88:</td><td class="cellleft">Rescriptor [package insert]. La Jolla, California: Agouron Pharmaceuticals, Inc; June 2001.</td></tr><tr><td valign="top" class="cellrightblue"><a name="89"> </a>89:</td><td class="cellleft">Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract #345]. 5th Conference on Retroviruses and Opportunistic Infections. Feb 1-5, 1998. Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="109"> </a>109:</td><td class="cellleft">Justesen US, Klitgaard NA, Brosen K, Pedersen C. Amprenavir is an effective inducer of delavirdine metabolism [abstract #442-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 February 24-28; Seattle, Washington.</td></tr><tr><td valign="top" class="cellrightblue"><a name="110"> </a>110:</td><td class="cellleft">Tran JQ, Petersen C, Garrett M, et al. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther 2002;72:615-26.</td></tr><tr><td valign="top" class="cellrightblue"><a name="141"> </a>141:</td><td class="cellleft">Justesen US, Klitgaard NA, Brosen K, et al. Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. J Antimicrob Chemother 2004; May 18th</td></tr><tr><td valign="top" class="cellrightblue"><a name="204"> </a>204:</td><td class="cellleft">Booker B, Smith P, Forrest A, et al. Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) and N-delavirdine (N-DLV) [abstract #A-490]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois.</td></tr></table></div></div><div class="footer"><p class="footerlinks"><a href="InSite?page=About">About</a> | <a href="InSite?page=SM">Site Map</a> | <a href="fb?page=Feedback">Feedback</a> | <a href="InSite?page=Subscribe">Subscribe</a> | <a href="InSite?page=Donate">Donate</a> | <a href="InSite?page=Disclaimer">Disclaimer</a></p><p class="copyright"><a href="http://chi.ucsf.edu/" target="OffSite"><img src="images/footer/chi.gif" alt="UCSF - Center for HIV Information"/></a> HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2017, Regents of the University of California.</p></div></div></body></html>